Arkadios Wealth Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Arkadios Wealth Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$108K	Sell	35,206 -3,634	-9%	-$14K	﹤0.01%	1616
2025 Q4	$159K	Sell	38,840 -6,612	-15%	-$32.7K	﹤0.01%	1473
2025 Q3	$222K	Buy	45,452 +6,796	+18%	+$35.7K	0.01%	1314
2025 Q2	$196K	Buy	+38,656	New	+$190K	0.01%	1219
2025 Q1	–	Sell	-12,431	Closed	-$84K	–	1184
2024 Q4	$84K	Buy	+12,431	New	+$83.6K	﹤0.01%	893

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arkadios Wealth Advisors's RXRX Position: Q1 2026 in Review

Arkadios Wealth Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 9.4% in Q1 2026, selling an estimated $14K and leaving 35,206 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #1616.

Arkadios Wealth Advisors first reported a position in RXRX in Q4 2024 and has held it in 5 quarters since. The position peaked at $222K in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Arkadios Wealth Advisors held 35,206 shares of Recursion Pharmaceuticals worth $108K as of Q1 2026.
Arkadios Wealth Advisors sold 3,634 Recursion Pharmaceuticals shares in Q1 2026, an estimated $14K.
Recursion Pharmaceuticals made up ﹤0.01% of Arkadios Wealth Advisors's portfolio in Q1 2026, its #1616 holding.
Arkadios Wealth Advisors first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
Arkadios Wealth Advisors's Recursion Pharmaceuticals position peaked at $222K in Q3 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q1 2026, filed 18 May 2026.